In this week’s EuroBiotech Report, Neil Woodford’s fund got deeper into Circassia, pulled out of Sanofi and criticized GlaxoSmithKline for performing “poorly operationally.” Servier scooped up regional rights to Taiho Pharmaceutical’s refractory metastatic colorectal cancer drug in a $130 million (€115 million) deal. And more.

…read more

Source: Woodford doubles down on Circassia, Servier in $130M cancer deal, French biotechs eye NY cash


0 No comments